Fibromyalgia Impact Questionnaire
Also known as: FIQ, Fibromyalgia Impact, Fibromyalgia Questionnaire
The FIQ is the most widely used patient-reported outcome measure for fibromyalgia disease burden. Developed by Cynthia Burckhardt and colleagues in 1991, this 10-item questionnaire quantifies how fibromyalgia affects physical function, work capacity, depression, anxiety, sleep, pain, and fatigue. The revised version (FIQR, 21 items) offers enhanced psychometric properties and is the current standard in fibromyalgia clinical trials and practice.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
The FIQ or FIQR is indicated for assessing fibromyalgia burden across the clinical spectrum. Use cases include baseline assessment of disease impact to guide multimodal treatment planning, monitoring response to pharmacotherapy (pregabalin, duloxetine, milnacipran) or non-pharmacological interventions (exercise, cognitive-behavioral therapy, patient education), outcome measurement in clinical trials as a primary or co-primary endpoint, research examining mechanisms and long-term natural history, and quality improvement in rheumatology practice. The FIQR is preferred over the original FIQ for new studies due to superior psychometric properties. Both instruments are appropriate for fibromyalgia populations but less suitable for other rheumatologic conditions unless adapted.
Strengths & limitations
- Fibromyalgia-specific content—developed directly from fibromyalgia patients, capturing disease-relevant domains (fatigue, 'fibro fog', sleep, widespread pain) that generic QoL measures miss
- Extensively validated—used in hundreds of fibromyalgia trials and studies, with demonstrated reliability (Cronbach's α 0.70-0.95), test-retest stability, and responsiveness to pharmacological and behavioral treatments
- FIQR improvements—the revised version (FIQR, 2009) addresses original FIQ limitations with expanded item set, refined scoring, domain subscales, and better psychometric performance
- Brief and feasible—original FIQ 10 items or FIQR 21 items both suitable for routine clinical use; completion time 5-15 minutes is acceptable for most patients
- Free and widely available—unrestricted access for research and clinical use; downloadable forms and scoring algorithms from academic centers
- Accepted regulatory standard—FIQR is widely accepted by FDA and regulatory bodies as a primary outcome in fibromyalgia drug development
- Does not diagnose fibromyalgia—measures impact of presumed fibromyalgia; cannot establish diagnosis, which requires clinical criteria (2016 ACR criteria: widespread pain index + symptom severity scale). Must be used with clinical assessment and tender point examination where applicable.
- Modest correlation with objective measures—FIQ/FIQR correlates weakly with tender point count (r = 0.20-0.40) and imaging findings; patient-reported burden is often independent of clinical findings, highlighting the subjective nature of fibromyalgia
- Multiple versions—existence of original FIQ and FIQR can cause confusion in comparing studies; specify version used and ensure consistency in longitudinal assessment
- Potential overestimation with comorbidities—FIQ/FIQR does not distinguish pain/fatigue/depression specific to fibromyalgia from that due to comorbid depression, hypothyroidism, or sleep apnea; assess and manage comorbidities concurrently
- Score interpretation context-dependent—clinical meaningfulness of a given FIQR score varies by disease severity, treatment phase (newly diagnosed vs. long-standing), and individual patient priorities
Frequently asked
Should I use the original FIQ or the revised FIQR?
Use FIQR for new studies, trials, and clinical practice. It has superior psychometric properties, more consistent 0-10 item scaling, and is the current regulatory standard. If comparing longitudinally to historical FIQ data, either use conversion algorithms if available, or re-administer FIQR at all timepoints going forward to ensure consistency.
A patient has FIQR 95 (severe) but minimal tender points and no comorbidities. What explains this?
Fibromyalgia severity (FIQR) is independent of tender point count; widespread pain index and symptom severity are key diagnostic criteria, not necessarily tender point examination. This patient has significant subjective burden despite limited objective findings, typical of fibromyalgia. Ensure diagnosis is correct (2016 ACR criteria met), assess for other causes of fatigue (vitamin B12, thyroid), and consider multimodal treatment (exercise, CBT, medication if indicated) targeting patient-reported symptoms.
How much FIQR change indicates meaningful clinical improvement?
A change of 14-17 points on the original 0-100 FIQ scale is considered minimally important clinically. On FIQR (0-210 scale), proportional change would be approximately 28-34 points. Alternatively, percentage improvement (e.g., ≥20% reduction from baseline) can be used. Individual variation exists; some patients with high initial FIQR may regard 10-point improvement as meaningful, while others seek larger change. Combine FIQR change with patient global impression and functional goals.
Is FIQR appropriate for monitoring fibromyalgia in routine clinic?
Yes. Brief 21-item FIQR (10-15 minutes) is feasible for clinic use. Administer at baseline, 4-8 weeks after treatment initiation, and periodically thereafter (e.g., quarterly) to track response and guide therapy adjustments. Electronic administration or patient-completed forms during intake streamline workflow. FIQR is particularly useful in detecting non-responders early, enabling prompt treatment modification.
Sources
- Burckhardt, C. S., Clark, S. R., & Bennett, R. M. (1991). The Fibromyalgia Impact Questionnaire: Development and validation. The Journal of Rheumatic Diseases, 18(5), 728-735. link ↗
- Bennett, R. M., Friend, R., Jones, K. D., Ward, R., Han, B. K., & Ross, R. L. (2009). The Revised Fibromyalgia Impact Questionnaire (FIQR): Validation and psychometric properties. Seminars in Arthritis and Rheumatism, 39(6), 448-453. DOI: 10.1186/ar2783 ↗
- Häuser, W., Petzke, F., Üçeyler, N., & Köllner, V. (2012). Fibromyalgia. Nature Reviews Disease Primers, 1, 15022. link ↗
How to cite this page
ScholarGate. (2026, June 3). Fibromyalgia Impact Questionnaire. ScholarGate. https://scholargate.app/en/health-outcomes/fibromyalgia-impact-questionnaire
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- CHQHealth Outcomes↔ compare
- DLQIHealth Outcomes↔ compare
- EORTC QLQ-C30Health Outcomes↔ compare
- KDQOLHealth Outcomes↔ compare